| Business Summary | | Sepracor
Inc.
is
a
specialty
pharmaceutical
company
focused
on
the
cost-effective
development
of
potentially
safer,
purer
and
more
effective
drugs
that
are
improved
versions
of
widely
prescribed
pharmaceutical
compounds.
The
Company
develops
and
markets
these
drugs
by
leveraging
its
expertise
in
chiral
chemistry
and
pharmacology
with
its
experience
in
conducting
clinical
trials
and
seeking
regulatory
approvals
for
new
drugs.
Sepracor's
Improved
Chemical
Entities
pharmaceutical
development
program
has
yielded
an
extensive
portfolio
of
drug
candidates
intended
to
treat
a
broad
range
of
indications
in
respiratory
care,
urology,
gastroenterology,
psychiatry
and
neurology. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SEPR
researches,
develops
and
commercializes
products
for
the
synthesis,
separation
and
purification
of
pharmaceutical
compounds.
For
the
six
months
ended
6/01,
revenues
rose
58%
to
$78.2
million.
Net
loss
fell
less
than
1%
to
$85.3
million.
Revenues
reflect
an
increase
in
product
sales
due
to
the
sales
of
Xopenex.
Lower
loss
was
partially
offset
by
increased
costs
related
to
several
new
clinical
studies
and
higher
personnel
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Timothy Barberich, 53 Chairman,
CEO | $516K | $4.9M | William O'Shea, 51 Pres,
COO | 577K | 5.8M | David Southwell, 40 CFO,
Exec. VP, Sec. | 343K | 26.1M | Robert Scumaci, 41 Exec.
VP of Fin. and Admin. Treasurer | 275K | 10.0M | Paul Rubin, M.D., 47 Exec.
VP, Drug Devel. and ICE Research | 406K | 19.8M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|